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The antiarrhythmic efficacy and safety of oral encainide 
hydrochloride and quinidine sulfate were compared in 
a nine center double-blind crossover study in 187 out•
patients with benign or potentially lethal ventricular ar•
rhythmias. Patients with at least 30 premature ventric•
ular complexes/Ii were randomized to receive either 
encainide, 25 mg four times/day, or quinidine, 200 mg 
four times/day, for :z weeks. These doses were continued 
for another 2 weeks if a, 75% or greater reduction in 
premature ventricular compiexes was observed. If this 
reduction was not seen, encainide was increased to 50 
mg four times/day or quinidine to 400 mg four times/day 
for an additional 2 weeks. 
Both drugs produced a statistically significant reduc•
tion in premature ventriCUlar complex frequency com•
pare(l with baseline values. Encainide produced a sta•
tistically significant greater mean reduction in total 
premature ventricular complexes than did quinidine 
during the initial dose phase and after dose adjustment. 
More patients required dose iitcreases of quinidine (60%) 
than of encainide (51 %). Early discontinuation of treat-
Evidence is mounting that sudden cardiac death is due to 
ventricular tachyarrhythmias iri most patients (1) and that 
the patient at high risk for such an event can be identified 
by the presence of premature ventricular complexes and left 
ventricular dysfunction (2,3). A search for more effective 
and better tolerated antiarrhythmic agents has been under•
way for use in studies designed to test whether sudden 
cardiac death can be prevented by elimination of such ar•
rhythmias (2,4), Quinidine is the oldest and the most widely 
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ment resulting in advancement to the next study period 
occurred in 12 patients taking encainide and 38 patients 
taking quinidine (p < 0.05). PR and QRS intervals in•
creased significantly during encainide treatment, as did 
QTc and JT intervals during quinidine treatment. No 
adverse reactions resulted from these electrocardio•
graphic changes. 
Adverse reactions were more ~ommon with quinidine 
than with encainide. A proarrhythmic effect was noted 
in eight patients taking encainide (five had an increase 
in premature ventricular complex frequency and three 
an increase in the duration of asymptomatic ventricular 
tachycardia) and in four patients taking quinidine (one 
had an increase in premature ventricular complex fre•
quency and two an increase in the duration of asymp•
tomatic ventricular tachycardia; and syncope developed . 
in one) (p = NS). Thus, encainide appears to be more 
effective and has fewer sidE! effects than quinidine and 
may be a reasonable alternative to quinidine therapy for 
ventricular arrhythmias. 
(J Am Coli CardioI1986;7:9-16) 
prescribed antiarrhythmic agent in the United States (5) and 
studies (2,5-7) have established its effectiveness and safety 
in approximately 60 to 80% of patients with benign and 
potentially lethal ventricular arrhythmias. 
Encaihide is a potent new class Ie antiarrhythmic agent 
(2). It lengthens intraatrial, atrioventricular (A V) node, His•
Purkinje and intraventricular conduction (8). It has no sig•
nificant negative inotropic effect (9) and thus may be val•
uable in patients with severe left ventricular dysfunction 
who benefit most from control of ventricular arrhythmias. 
Placebo-controlled studies using appropriate standards (10) 
have demonstrated that encainide is effective in 70 to 80% 
of patients with ventricular arrhythmias. The effective dose 
appears to be between 25 and 50 mg three to four times/day 
(11-13). Aggravation of arrhythmias (proarrhythmia) from 
encainide has been previously reported in approximately 
10% of patients with benign and potentially lethal ventric-
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ular arrhythmias (11-13). Patients with more lethal arrhyth•
mias and more severe degrees of left ventricular dysfunction 
have a higher incidence of proarrhythmic events (14,15). 
Our study was designed to compare the safety and efficacy 
of encainide and quinidine with emphasis on the safety of 
initiating each agent in outpatients with benign or potentially 
lethal ventricular arrythmias. 
Methods 
Patient selection. Nine clinical centers enrolled patients 
18 years or older who demonstrated at least 30 premature 
ventricular complexes/h on a 24 hour Holter monitor re•
cording taken near the end of 1 week of placebo therapy 
(baseline). The initial placebo period was preceded by a 1 
week washout period in which all prior antiarrhythmic ther•
apy was discontinued and a qualifying Holter monitor re•
cording was obtained to determine eligibility. Patients were 
included in the study only if their ventricular arrhythmias 
required therapy in the judgment of the investigator. Patients 
were excluded if they had hemodynamically significant, 
severe, life-threatening ventricular arrhythmias (4) or a his•
tory of severe intolerance or allergic reaction to either en-
JACC Vol. 7, No.1 
January 1986:9-16 
cainide or quinidine. Patients were also excluded if they 
had evidence of sick sinus syndrome, required the presence 
of a pacemaker, had a baseline QRS duration of more than 
0.14 second, a PR interval of more than 0.24 second or a 
QTc interval of more than 0.50 second. Uncontrolled hy•
pertension, congestive heart failure, angina pectoris, seizure 
disorders, abuse of alcohol or significant renal or hepatic 
failure were other criteria for exclusion from the study. 
Patients with evidence of acute myocardial infarction or use 
of amiodarone within 90 days before enrollment were also 
excluded. 
Protocol (Table 1). This was a multicenter, 14 week, 
double-blind, randomized, crossover comparative study of 
encainide versus quinidine in outpatients. It included six 
consecutive periods: 1) washout; 2) initial placebo; 3) first 
active drug; 4) second placebo; 5) second active drug; and 
6) final placebo. After the initial 7 day washout period, 
patients qualifying (those with premature ventricular com•
plexes averaging 2:30/h) on the first 24 hour Holter monitor 
recording received placebo for 1 week and underwent a 
second Holter recording. Eligible patients were then entered 
into the first active drug period to receive either encainide 
or quinidine for 4 weeks. At the end of 2 weeks, the dose 
Table 1. Procedures and Observations in the Encainide-Quinidine Comparison Study 
Period (weeks) 
First Active Second Active Final 
Procedures and Washout Placebo Drug* Placebo Drug* Placebo 
Observations (I) (I) (3 to 6) (7 to 8) (9 to 12) (13 to 14) 
24 hour Holter tnonitor X X X X(X)t X X 
Plasma for assay (2 h X X X X X 
postdose) 
Concomitant X X X X X X 
medications 
Medical history X 
Physical examination X X 
and vital signs 
Laboratory tests X X 
12 lead ECG (2 h X X X X X X 
postdose) 
CheSt X-ray film X 
(unless done within 6 
months) 
Capsule count X X X X X 
Interim assessment X X X X 
(induding vital signs) 
On-therapy condition X X X X X 
reports 
Final assessment X 
Blood samples for X X X 
serum digoxin assay 
(21 pts.) 
*Procedures and observations were perfonned twice (near the end of the second and fourth week) in each 
active drug period. tlf a patient's premature ventricular complex rate did not return to at least 50% of baseline 
level (first placebo), a repeat 24 hour Holter recording was perfonned to detennine whether the patient was 
eligible for participation in the second active drug period. ECG = electrocardiogram; pts. = patients. 
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of active medication could be increased if a 75o/c reduction 
in premature ventricular complex frequency compared with 
the initial placebo period had not been obtained. A two 
week second placebo period followed the first active drug 
period. During this second placebo penod a reappearance 
of at least 50% of the baseline premature ventricular com~ 
plex frequency was required for continuatIOn In the study 
Patients eligible to contmue received the alternate medi•
cation in the second active period in a manner identical to 
that of the first active drug period. The study ended with a 
2 week final placebo penod in which a 24 hour Holter 
recording was obtained. 
All placebo and active drug formulatIOns were identical 
in appearance and were prepackaged, labeled and provided 
in individual dose packets. The quinidine capsules used in 
the study were bioequivalent to commercially available 
quinidine sulfate capsules (Eli Lilly, USP, Pulvule No. 239). 
The initial dose of encainide was 25 mg four times/day and 
the adjusted dose was 50 mg four times/day. The initial 
dose of quinidine sulfate was 200 mg four times/day and 
the adjusted dose was 400 mg four times/day. Any patient 
who had an adverse reaction requiring discontinuation of 
the active agent was entered directly into the next period of 
the protocol or withdrawn from the study. The protocol was 
reviewed and approved by each center's institutional review 
board, and all patients were required to give written in•
formed consent before entering the study. 
Data analysis. The primary criterion for efficacy was a 
75% reduction from baseline value in the average hourly 
premature ventricular complex frequency as determined by 
24 hour Holter recordings. The baseline for the first active 
drug period was the initial placebo period (the second week 
of study) and the baseline for the second active drug period 
was the second placebo period. Additional comparisons were 
made of the percent suppression of paired premature ven•
tricular complexes (couplets) and premature ventricular 
complexes occurring in runs of three or more (ventricular 
tachycardia). Evaluations of drug safety included measure•
ments of vital signs, electrocardiogram~, clinical laboratory 
tests, physical examinations, reports of conditions during 
therapy and proarrhythmia assessment~ <Table I) 
The criterion for dejinm~ a proarrhythm/c event (16) was 
the appearance at any time during the active drug penod of 
the study of a more severe ventricular arrhythmia than had 
been previously documented. An increase in the hourly av•
erage of premature ventricular complex frequency over that 
of the initial placebo arrhythmia baseline frequency was also 
used (16). Unexplained syncope was a)<;o considered a 
pro arrhythmic response in this analYSIS, 
The Holter monitor tapes were analy:ed by an indepen•
dent research facility (Cardio-Data Systems of United Med•
ical Corporation) using a complete computer-generated re•
port for each tape analyzed. To ensure accuracy, a quality 
control program was performed using hand-counted, 24 hour 
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Holter tapes randomly inserted into the system. In addition, 
to ensure reproducibility, the same tapes were repeatedly 
analyzed at different times. Precise quantitation of the fre•
quency of premature ventricular complexes, couplets and 
beats of ventricular tachycardia were performed. Validation 
of this method has been reported previously (6). To reduce 
the right skewness of their distribution, the hourly rates of 
total premature ventricular complexes, couplets and beats 
of ventricular tachycardia were transformed by adding one 
and taking the natural logarithm before computing the change 
from the appropriate placebo baseline study. 
Statistics. A linear model of analysis of variance was 
used on data from patients who completed both active drug 
periods to determine whether data from all study centers 
could be pooled for analysis of efficacy and to compare the 
efficacy of the two agents. Another linear model was also 
used to analyze data from all patients who completed the 
first active drug periods. 
Results 
Patient characteristics. There were 187 patients ran•
domized at the nine study centers. The mean age of the 187 
patients was 60 years (range 26 to 86) and 76 (41%) were 
65 years of age or older; 133 (71 %) were male and 152 
(81 %) were white. One hundred seventy-three patients com•
pleted the first active drug period and 134 (72%) completed 
both active drug periods (Table 2). Ninety-five patients were 
randomized to the encainide-quinidine sequence and 92 to 
the quinidine-encainide sequence. Of the 187 patients, 154 
(82%) had received a total of 384 prior antiarrhythmic treat•
ments. Seventy-three percent of these prior treatments were 
discontinued because of inadequate efficacy or side effects, 
or both, 
Fifty-six (30%) of the 187 patients randomized to this 
trial did not complete all 6 periods of the study. Five patients 
discontinued the study because of conditions during therapy 
and five others because of intercurrent illness. Four addi•
tional patients died during the study (two taking placebo 
and two taking encainide). Other reasons for not completing 
the study trial were: administrative problems (n = 7 patients 
[4%]); patient noncompliance (n = 6 [3% l); patient lost to 
follow-up (n = 1); insufficient premature ventricular com•
plex frequency during the first placebo period (second week 
of study) (n = 6 [3%]) and insufficient premature ventricular 
complex return during the second placebo period (n = 21 
[ I 1 % J). One additional patient discontinued therapy because 
his prior physician prescribed another antiarrhythmic med•
ication, Of the 56 patients who did not complete the study 
trial, 29 had been assigned to the encainide then quinidine 
sequence, and 27 to the quinidine then encainide sequence. 
One hundred seventy-three (93%) of the patients received 
concomitant medications, which included cardiac glyco•
sides in 42 (22%), diuretic drugs in 58 (31 %), coronary 
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Table 2. Number of Patients Randomized and Completing the First Active Drug Period and 
Both Active Drug Periods 
Study Randomized Completed First Active Completed Both Active 
Center (n) Drug Period (n) Drug Periods (n [0/0)) 
50 
2 14 
3 26 
4 23 
5 26 
6 7 
7 8 
8 23 
9 10 
Total 187 
vasodilators in 69 (37%), beta-adrenergic blockers in 32 
(17%), calcium channel blockers in 25 (13%) and antihy•
pertensive medications in 61 (33%). Overall, 153 patients 
received encainide and 154 received quinidine. 
Efficacy. Figure 1 shows the median total of premature 
ventricular complexes per hour by drug and trial period. 
Phase I refers to the initial dosing period of an active drug 
phase and phase II to the dose adjustment phase of an active 
drug period. Encainide and quinidine produced a statistically 
significant reduction (p < 0.05) in premature ventricular 
complexes when compared with in baseline values. En•
cainide produced a greater reduction in premature ventric-
Figure 1. The median number of premature ventricular complexes 
(PVCs)/h is displayed for the various periods of the encainide•
quinidine comparative trial. The qualifying data were obtained 
after 7 days without prior antiarrhythmic therapy and the baseline 
data after 1 week of placebo treatment. Data are divided for en•
cainide (Enc) and quinidine (Qui) for baseline, drug phase I (initial 
dose) and phase II (adjusted dose). The final placebo washout 
Holter monitoring data were obtained after about 14 days without 
active drug. The asterisk indicates a significant difference from 
baseline at the 5% level using the Wilcoxon signed rank test. The 
dagger indicates a significant difference between encainide and 
quinidine in the crossover analysis at the 5% level. 
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ular complexes than did quinidine (p < 0.05) and with 
upward dose adjustment, both encainide and quinidine 
produced even greater reductions in total premature ven•
tricular complexes. Although upward dose adjustment was 
required in more patients receiving quinidine (60%) than 
encainide (51 %), encainide stilI reduced total premature 
ventricular complexes more than quinidine, a statistically 
significant difference. 
Figure 2 details the percent of patients with events of 
ventricular tachycardia and demonstrates that both encain•
ide and quinidine produced statistically significant decreases 
from baseline values. During the initial dosing period, en•
cain ide was more effective than quinidine (p < 0.05) in 
reducing the percent of patients with ventricular tachycardia. 
After dose adjustment, fewer patients had events of ven•
tricular tachycardia but the difference between encainide 
and quinidine was no longer statistically significant. Figure 
3 shows the percent of patients who responded to active 
drug treatment with a 75% or greater reduction in total 
Figure 2. Percent of patients with ventricular tachycardia (VT) 
events present during each of the study periods. For definition of 
the different periods and abbreviations see Figure I. 
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Figure 3. Percent of patients responding at 75% or greater re•
duction in total premature ventricular complexes/h is demonstrated 
for encainide (Enc) and quinidine (Qui) during initial dose (phase 
I) and adjusted dose (phase II) periods in the trial. The dagger 
indicates a significant difference between encainide and quinidine 
using Fisher's exact test at the 5% level. 
premature ventricular complexes, During the initial dosing 
period a greater percent of patients responded to encainide 
than to quinidine (p < 0.05). However, the difference be•
tween the two drugs was no longer statistically significant 
after dose adjustment. During initial dosing, 81% of the 
patients had a 75% reduction from baseline in ventricular 
tachycardia beats per hour with encainide treatment com•
pared with a 60% reduction with quinidine treatment (p < 
0.05). After dose adjustment, 84% of the patients taking 
encainide responded compared with 78% of those taking 
quinidine (p == NS). 
Of the 153 patients who received encainide in this study, 
106 (79%) continued in a long-term encainide follow-up 
study. There was no significant difference in the response 
to encainide or quinidine treatment with regard to sex, race, 
New York Heart Association functional class, previous his•
tory of ventricular tachycardia, congestive heart failure or 
myocardial infarction, baseline conduction abnormality or 
baseline frequency of premature ventricular complexes. In 
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patients younger than 65 years of age, there was a statis•
tically significant greater reduction in premature ventricular 
complex frequency during encainide than during quinidine 
treatment, whereas in patients older than 65 years of age, 
quinidine and encainide similarly reduced total premature 
ventricular complex frequency. 
Safety. Five patients were withdrawn prematurely from 
the study because of intercurrent illness and five others 
because of conditions during therapy (four receiving placebo 
and one receiving quinidine). Conditions during therapy 
were reported in 159 (85%) of 187 patients during placebo 
or active drug treatment periods, or both. Seventy-five per•
cent of the patients (114 of 153) taking encainide had 281 
on-therapy conditions whereas 80% (123 of 154) of the 
patients taking quinidine had 407 on-therapy conditions. 
Table 3 details the relative side effects observed. Side 
effects that required early discontinuation of an active drug 
and advancement into the next placebo period occurred in 
12 patients taking encainide as compared with 38 patients 
taking quinidine (p < 0.001). Of the 12 patients who dis•
continued encainide and advanced to the next phase, 6 stopped 
during the initial dose phase and 6 soon after the dose had 
been increased. Discontinuations during encainide therapy 
were for side effects primarily related to the central nervous 
system (for example, visual disturbances and dizziness). Of 
the 38 patients who discontinued quinidine treatment and 
advanced to the next study period, 27 stopped during initial 
dosing and 11 soon after the dose increase. Most of the side 
effects from quinidine were related to the gastrointestinal 
system and were primarily diarrhea and nausea. Only five 
patients were withdrawn from the study because of on•
therapy conditions other than intercurrent illness. One pa•
tient was withdrawn because of diaphoresis and vomiting 
during the first placebo period, two (one because of nausea 
and worsening congestive heart failure and one because of 
malaise and abdominal numbness) during the second pla•
cebo period, one because of an altered level of consciousness 
on quinidine and one because of nausea and frequent pre•
mature ventricular complexes during the final placebo pe•
riod. All three patients who discontinued therapy during the 
second and final placebo periods were taking quinidine. 
Table 3. Incidence of Side Effects on Active Drug Therapy 
Encainide (n = 153) Quinidine (n = 154) p Value 
Dizziness 24 (15.7) 23 (14.9) 0.981 
Visual disturbances 18 (11.8) 10 (6.5) 0.117 
Headache 13 (8.5) 24 (15.6) 0.083 
Asthenia 10 (6.5) 21 (13.6) 0.061 
Nausea 13 (8.5) 16 (10.4) 0.710 
Diarrhea* 14 (9.2) 60 (39.0) 0.001 
Skin rash 3 (2.0) 7 (4.5) 0.340 
Fever* 0(0.0) 12 (7.8) 0.001 
*Significant differences. Numbers in parentheses represent percent of patients. 
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More patients receiving quinidine than those receiving 
encainide had fever (12 versus 0), malaise (6 versus 0) and 
diarrhea (60 versus 14). Headache occurred in 9% of patients 
receiving encainide compared with 16% of those receiving 
quinidine. Conversely, dizziness occurred in 16% of pa•
tients taking encainide versus 15% of those taking quinidine, 
and blurred vision in 9% taking encainide compared with 
6% taking quinidine (p = NS). Five patients had on-therapy 
conditions suggesting exacerbation of congestive heart fail•
ure, one patient receiving both encainide and quinidine and 
two patients receiving either encainide or quinidine. In three 
of these five patients no action was taken, in one furosemide 
was increased and in the remaining patient anti-ischemic 
therapy was increased. 
EtTects on electrocardiographic intervals and other 
measures (Table 4). Dose-related increases in electrocar•
diographic intervals followed the use of both encainide and 
quinidine. PR and QRS intervals were increased during 
encainide therapy, whereas the QTc and JT intervals were 
increased during quinidine therapy. Five patients taking en•
cainide had an increase in PR interval to 0.28 to 0.44 second 
and three patients had an increase in QRS interval to 0.20 
to 0.24 second. No patient developed second or third degree 
heart block or obvious clinical change in baseline medical 
condition due to changes in PR and QRS intervals. 
No clinically significant changes in blood pressure and 
heart rate were noted in this study and there was no obvious 
relation of any changes in laboratory test with an active drug 
regimen that was clinically significant. 
Proarrhythmic etTects. Twelve patients met the study 
criteria for proarrhythmia during this trial. In eight patients 
proarrhythmia was noted during encainide therapy. In five, 
an increase in premature ventricular complex frequency was 
documented and in three the occurrence of an II, 27 and 
13 beat run of asymptomatic ventricular tachycardia was 
noted. In four patients taking quinidine, proarrhythmia was 
noted. One of the four had an increase in premature ven•
tricular complex frequency, two had a 12 beat run of asymp•
tomatic ventricular tachycardia and one had an unexplained 
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loss of consciousness for 20 minutes with presyncopal symp•
toms. This patient did not have an objective documentation 
of proarrhythmia, but is included because this possibility 
could not be excluded. One patient had an increase in pre•
mature ventricular complex frequency defined as proar•
rhythmia while receiving both encainide and quinidine. In 
one patient each taking quinidine and encainide with a 12 
and 13 beat run of ventricular tachycardia, respectively, 
these events disappeared when the patient began taking the 
higher dose of the drug. No patient had hemodynamic symp•
toms from the change in premature ventricular complex 
frequency or the number of beats in ventricular tachycardia 
events and no patient was withdrawn prematurely from ther•
apy because of these episodes. 
Four patients died in this trial; two had been receiving 
encainide, one was in the first placebo period and one was 
in the second placebo period after quinidine treatment. One 
patient died after 7 days of treatment with encainide, 25 mg 
four times/day, probably because of a new myocardial in•
farction with coronary artery bypass graft closure. The sec•
ond patient also died after 7 days of receiving encainide, 
25 mg four times/day. She had a recent exacerbation of 
angina pectoris and had severe nocturnal anginal episodes 
during the first placebo period. It was believed that her death 
was not related to encainide. A death of a patient due to 
ventricular fibrillation after 7 days of placebo following 27 
days of quinidine dosing was notable in that while receiving 
quinidine he complained of shortness of breath and pul•
monary congestion and had a 5 pound (2.25 kg) weight 
gain. Another death after 2 days of taking predrug placebo 
was possibly due to an arrhythmia. 
Encainide and digoxin interaction. Serum digoxin lev•
els were measured in 21 patients (Table 1). During encainide 
treatment there was no statistically significant difference in 
serum digoxin levels between baseline and encainide treat•
ment (range 0.5 to 2.1 versus 0.3 to 2.2 ng/ml, respectively) 
or between the two encainide dose levels. During quinidine 
therapy, there was a statistically significant dose-related in•
crease in serum digoxin levels (p < 0.01). 
Table 4. Average Electrocardiographic Interval Increases from Baseline Study 
Treatment 
Encainide 
Initial dose 
Adjusted dose 
Quinidine 
Inittal dose 
Adjusted dose 
PR(0.17)* 
0.022 
0.030 
0.005 
0.007 
*Baseline values. All values in seconds. 
QRS (0.09)* 
0.011 
0.Ql8 
0.001 
0.005 
Interval 
QTc (0.42)* 
0.018 
0.020 
0.025 
0.034 
JT (0.29)* 
0.001 
0.001 
0.024 
0.029 
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Discussion 
This multicenter, double-blind, crossover trial compared 
oral encainide (25 to 50 mg four times/day) with oral quin•
idine (200 to 400 mg four times/day) in the treatment of 
benign and potentially lethal ventricular arrhythmias. Quin•
idine was chosen as the comparative agent because of its 
common use in the United States and its common reference 
status when studying new antiarrhythmic drugs. The results 
of this study reveal that encainide and quinidine each produced 
a statistically significant reduction in total premature ven•
tricular complex frequency when compared with baseline 
values; encainide produced a greater reduction than did quin•
idine during both the initial dose and adjusted higher dose 
treatment. Suppression of ventricular tachycardia was also 
significantly better during encainide than during quinidine 
therapy in the initial dose period, although this difference 
was no longer significant after dose adjustment. More pa•
tients required an increase in the dose of quinidine (60%) 
than of encainide (51 % ) . 
These results are comparable with those in a study by 
Sami et al. (17), which was a longitudinal, crossover, com•
parative study using a fixed dose of quinidine and encainide 
in 20 men over 8 weeks. Encainide at 50 mg four times/day 
suppressed all premature ventricular complexes in 44% of 
the patients and reduced the frequency by 80% or more in 
88% of the patients. When ventricular tachycardia beats 
were present, 100% reduction resulted in all patients. Quin•
idine at a dose of 300 mg four times/day did not totally 
suppress premature ventricular complexes in any patient and 
resulted in an 80% reduction in such complexes in less than 
50% of the patients. In only 50% of the patients was there 
complete suppression of ventricular tachycardia. This mul•
ticenter study confirms these preliminary data in patients 
who have a higher frequency of ventricular arrhythmia, 
using two different drug dosing levels and more frequent 
Holter monitoring. 
Drug tolerance. Encainide was better tolerated in this 
study than was quinidine. The prevalence and nature of side 
effects are similar to those reported from previous studies 
(5,6,11-13). The common side effects noted with encainide 
therapy were dizziness and blurred vision, whereas the 
prominent side effects with quinidine were gastrointestinal 
symptoms and fever. Encainide increased the PR and QRS 
intervals in a manner with its electrophysiologic effects (8). 
None of these changes required discontinuation of the drug 
nor did second or third degree heart block occur. We, there•
fore, have suggested that patients cont~nue receiving en•
cainide despite changes in the PR and QRS intervals up to 
0.28 and 0.18 second, respectively. There was no evidence 
that any electrocardiographic change in this study was re•
lated to side effects or new symptoms. 
Recommendations. Neither drug in the doses used caused 
changes of clinical significance in vital signs or laboratory 
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variables. Proarrhythmic effects were documented in terms 
of exacerbation of the frequency of premature ventricular 
complexes or the number of beats in a ventricular tachy•
cardia event. None of these proarrhythmic events resulted 
in hemodynamic consequences and, therefore, we believe 
that encainide and quinidine can be safely initiated in an 
outpatient setting in patients with benign or potentially lethal 
ventricular arrhythmias. These results are similar to those 
seen when comparing quinidine with flecainide, another 
class Ie antiarrhythmic agent (6). That study also found no 
hemodynamically significant proarrhythmic event from out•
patient initiation of flecainide or quinidine. However, the 
use of encainide or flecainide in patients with lethal ven•
tricular arrhythmias (2) requires more caution, including 
inhospital monitoring, slow dose escalation schedule and 
avoidance of high doses (for example, >200 mg/day of 
encainide) to maximize safety (15,16). 
Thus, encainide appears to be more effective than quin•
idine (at the doses used in this study) with fewer side effects 
and may be a reasonable alternative to quinidine therapy 
for benign and potentially lethal ventricular arrhythmias. 
Appendix 
Centers Comprising the Encainide-Quinidine Research Group 
1. National Cardiovascular Research Center, Haddonfield, NJ. 
Joel Morgattroth, MD, Chris Baessler, RN. 
2. Hennepin County Medical Center, Minneapolis, MN. Morrison 
Hodges, MD, Teresa Larson, RN. 
3. North County Cardiovascular Medical Group, Inc., Encinitas, 
CA. Peter E. Pool. MD, Antone E. Salel, MD, Shirley Seagren, RN. 
4. William Beaumont Hospital, Division of Cardiovascular Dis•
eases, Royal Oak, MI. James R. Stewart, MD, Sheri Londal, RN. 
5. Albert Einstein College of Medicine, Bronx, NY. John Somberg, 
MD, Deborah Keefe, MD, Sharon Williams, PA-C. 
6. 1315 North Arlington Avenue, Suite 100, Indianapolis, IN. Don 
Ziperman, MD, Chris Lathrop, RN. 
7. 2475 East 22nd Street, Suite 611, Cleveland, OH. Alfred G. 
Kitchen, MD, Pam Hanigosky, RN. 
8. Cardiology Division, Veterans Administration Hospital, Wash•
ington, D.C. Robert DiBianco, MD, Sheryl Sturm, RN, Carol Hinzman. 
PA-C. 
9. 104 Selma Drive, Winchester, VA. JamesC. Laidlaw, MD, Philip 
J. O'Donnell, MD, Linda Stollings, RN. 
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